80 related articles for article (PubMed ID: 1660165)
1. WR2721 protection of bone marrow in 131I-labeled antibody therapy.
Badger CC; Rasey J; Nourigat C; Fisher DR; Hui TE; Wu ZM; Bernstein ID
Radiat Res; 1991 Dec; 128(3):320-4. PubMed ID: 1660165
[TBL] [Abstract][Full Text] [Related]
2. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
3. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
4. Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
Grdina DJ; Carnes BA; Grahn D; Sigdestad CP
Cancer Res; 1991 Aug; 51(16):4125-30. PubMed ID: 1651155
[TBL] [Abstract][Full Text] [Related]
5. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
6. Drug combination against single drug treatment in radiation protection of the bone marrow CFU.
Bisht KS; Uma Devi P; Jagetia GC; Kamath G
Strahlenther Onkol; 1990 Aug; 166(8):545-8. PubMed ID: 2168583
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
8. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.
DeNardo DA; DeNardo GL; Yuan A; Shen S; DeNardo SJ; Macey DJ; Lamborn KR; Mahe M; Groch MW; Erwin WD
J Nucl Med; 1996 Dec; 37(12):1970-5. PubMed ID: 8970516
[TBL] [Abstract][Full Text] [Related]
9. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
Colapinto EV; Zalutsky MR; Archer GE; Noska MA; Friedman HS; Carrel S; Bigner DD
Cancer Res; 1990 Mar; 50(6):1822-7. PubMed ID: 2407345
[TBL] [Abstract][Full Text] [Related]
11. Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies.
Badger CC; Krohn KA; Shulman H; Flournoy N; Bernstein ID
Cancer Res; 1986 Dec; 46(12 Pt 1):6223-8. PubMed ID: 3779642
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
13. Radioprotective effect of combinations of WR-2721 and mercaptopropionylglycine on mouse bone marrow chromosomes.
Uma Devi P; Prasanna PG
Radiat Res; 1990 Nov; 124(2):165-70. PubMed ID: 2174174
[TBL] [Abstract][Full Text] [Related]
14. Tissue-protective effects of fullerenol C60(OH)24 and amifostine in irradiated rats.
Trajković S; Dobrić S; Jaćević V; Dragojević-Simić V; Milovanović Z; Dordević A
Colloids Surf B Biointerfaces; 2007 Jul; 58(1):39-43. PubMed ID: 17317115
[TBL] [Abstract][Full Text] [Related]
15. Determinants of the antitumor effect of radiolabeled monoclonal antibodies.
Knox SJ; Levy R; Miller RA; Uhland W; Schiele J; Ruehl W; Finston R; Day-Lollini P; Goris ML
Cancer Res; 1990 Aug; 50(16):4935-40. PubMed ID: 2379158
[TBL] [Abstract][Full Text] [Related]
16. Prevention of radiolysis of monoclonal antibody during labeling.
Chakrabarti MC; Le N; Paik CH; De Graff WG; Carrasquillo JA
J Nucl Med; 1996 Aug; 37(8):1384-8. PubMed ID: 8708780
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4.
Schmidberger H; Buchsbaum DJ; Blazar BR; Everson P; Vallera DA
Cancer Res; 1991 Apr; 51(7):1883-90. PubMed ID: 2004371
[TBL] [Abstract][Full Text] [Related]
18. Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody.
Badger CC; Krohn KA; Peterson AV; Shulman H; Bernstein ID
Cancer Res; 1985 Apr; 45(4):1536-44. PubMed ID: 3978621
[TBL] [Abstract][Full Text] [Related]
19. Intraoral manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis.
Epperly MW; Carpenter M; Agarwal A; Mitra P; Nie S; Greenberger JS
In Vivo; 2004; 18(4):401-10. PubMed ID: 15369176
[TBL] [Abstract][Full Text] [Related]
20. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.
Buchegger F; Pfister C; Fournier K; Prevel F; Schreyer M; Carrel S; Mach JP
J Clin Invest; 1989 May; 83(5):1449-56. PubMed ID: 2708519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
